~" To clarify the contribution of vasoconstrictor prostaglandins to the hypoperfusion state typically foliowing total global cerebral ischemia, 14 mongrel dogs were subjected to 11 minutes of global cerebral ischemia They were then randomly assigned to receive either no treatment or an intravenous bolus of the calcium channel blocker nimodipine, l0 t~g/kg, 15 minutes after ischemia followed by a continuous infusion of nimo,tipine, 1.0 t~g/kg/min. Thromboxane (Tx) A2 production, as measured by cerebral venous levels of TxB2 (the stable metabolite of TxA2) increased similarly in the two groups. In contrast to previous studies, mean postischemic cerebral blood flow did not increase sufficiently in the nimodipine-treated group to achieve statistical significance. These data suggest that the improved neurological outcome associated with nimodipine treatment following global cerebral ischemia does not relate to reduced levels of the prostaglandin precursor arachidonate.
O
NLY 30% of patients hemodynamically resuscitated from in-hospital cardiac arrest (and the associated global cerebral ischemia) are ultimately discharged from the hospital without significant neurological deficit. ~ Following global cerebral ischemia, animals undergo a short period of relative cerebral hyperperfusion followed by prolonged severe cerebral hypoperfusion. 2~ This sustained decrease in cerebral blood flow (CBF) after global cerebral ischemia has been implicated in the progression of neurological deficits following resuscitation. 18 Loss of calcium homeostasis during ischemia causes intracellular calcium to rise to levels greater than 10 -4 M/liter? 6 Increased calcium levels activate phospholipase A2, which mediates the release of arachidonic acid from cell membranes. 5 Arachidonic acid is metabolized to the leukotrienes by lipoxygenase and to prostaglandins by cyclo-oxygenase. Increased release of vasoconstrictor prostaglandins has been documented following global cerebral ischemia. 7 Thromboxane (Tx) A2 (a cerebral vasoconstrictor) and prostacyclin (PGI2) (a cerebral vasodilator) are metabolites of cyclo-oxygenase.1 Inhibition of TxA2 production following global cerebral ischemia is associated with an improvement in postischemic hypoperfusion. 7 The calcium entry blocker nimodipine increases CBF after 10 minutes of global cerebral ischemia in cats and dogs, whether administered before or after the insult. 1~176 The following study was performed to determine whether nimodipine exerts its therapeutic effect by blocking the postischemic release of the vasoconstrictor TxA2.
Materials and Methods
This study was approved by the institutional animal care committee. Fourteen mongrel dogs, each weighing 15 to 25 kg, were anesthetized with intravenous sodium thiopental, 20 mg/kg, and paralyzed with intravenous pancuronium, 2.0 mg/kg. Each animal was endotracheally intubated and ventilated with a 0.4 fraction of inspired oxygen (FiO2), a tidal volume of 20 ml/kg, and a ventilatory frequency adjusted to maintain PaCO2 between 35 and 45 mm Hg. Halothane, 1.0%, was administered during the surgical preparation.
Through a percutaneously inserted femoral arterial catheter, systemic arterial pressure was recorded using a Gould P23 transducer connected to an oscillograph.* A No 7.5 French pulmonary artery catheter was then inserted through a right external jugular vein cutdown. A retrograde jugular catheter was inserted cephalad * Oscillograph, Model 78D, manufactured by Grass Instruments Co., Quincy, Massachusetts. until resistance was encountered; it was then withdrawn 2 m m and secured. Previous studies from this laboratory confirm the similarity between jugular venous and sagittal sinus levels of the metabolites of TxA2 following global cerebral ischemia. 7"13
Each animal was placed in the left lateral decubitus position, and a thoracotomy was performed in the fifth right intercostal space. Bupivacaine, 1.0 mg/kg, was infiltrated into the thoracotomy wound. The azygos vein was isolated and ligated. The superior and inferior venae cavae were dissected free, encircled with ligatures, and then loosely secured. The pericardium was incised, and the aorta was exposed and encircled with a vascular clamp. A No. 16 flexible silicone catheter was inserted into a pulmonary vein and passed into the left atrium. The thoracotomy wound was loosely approximated, and halothane was discontinued. Sixty percent nitrous oxide was administered and fentanyl, 5.0 ug/kg, was given intravenously. Thirty minutes were allowed to elapse prior to collecting baseline data.
After the baseline data were recorded, the FiO2 was increased to 1.0, immediately after which the inferior vena cava was occluded, followed by simultaneous occlusion of the superior vena cava and aorta. Occlusion was maintained for 11 minutes. Thirty seconds prior to release of the ligatures, sodium bicarbonate, 1 mEq/kg, was infused into a peripheral vein and the ventilatory rate temporarily doubled in anticipation of postischemic respiratory and metabolic acidosis. No other resuscitative drugs were administered. After 11 minutes of global cerebral ischemia, the inferior vena cava, the aorta, and then the superior vena cava were sequentially unclamped. Ten minutes following reperfusion, the FiO2 was decreased to 0.4 and 60% nitrous oxide was resumed. Animals were then randomly assigned to one of two groups. The treatment group (seven dogs) received an intravenous bolus of nimodipine, 10 ug/kg, 15 minutes following the relief of global cerebral ischemia, and then a continuous infusion of nimodipine, 1.0 t~g/kg/min. The control group (seven dogs) received equivalent volumes of saline.
Measurements were taken immediately before occlusion and 10, 30, and 60 minutes following the 1 lminute occlusion period. Blood samples were collected from the jugular vein and the systemic arterial catheter for radioimmunoassay of TxB2, which is the stable hydrolysis product of TxA2. In addition, 60 minutes following global cerebral ischemia, cerebrospinal fluid was collected for TxB2 analysis. Other data collected at corresponding time intervals included arterial blood pressure, cardiac output, central venous pressure, heart rate, and arterial pH, PaCO2, and PaO> Jugular venous pH, PaCO2, and PaO2 were measured in blood taken from the retrograde jugular catheter. The CBF was determined before and 30 and 60 minutes after ischemia using 15-urn dextran microspheres and the arterial reference method. 9 The microspheres were labeled with scandium-46, strontium-85, and tin-113. Brain samples were cut into paired 3-gm sections, counted in a gamma counter,t and regional and global CBF were analyzed. Immunoreactive TxB2 was assayed directly in plasma by standard double-antibody radioimmunoassay techniques s'2~ from simultaneous 5.0-ml samples of blood withdrawn from the aortic and jugular vein catheters into sterile syringes. These were immediately transferred to test tubes containing 0.5% ethylenediaminetetra-acetic acid and indomethacin (25 ug/ml whole blood) and maintained on ice until centrifugation at 1500 G at 4"C for 15 minutes. The plasma was aspirated and placed in polypropylene test tubes, which were stored at -2 0 " C until assayed.
All data were analyzed using analysis of variance of repeated measures; p < 0.05 was considered significant for changes in TxB2 and CBF.
Results
Both arterial and venous levels of TxB2 increased following global cerebral ischemia (Fig. 1) . Within the nimodipine-treated and the control groups, jugular venous TxB2 levels increased significantly relative to baseline. The jugular venous levels increased substantially more than the arterial levels. The resulting increased venous-arterial gradient for TxB2 indicated production of TxB2 by the brain or cerebral vasculature (Table 1) . However, there were no significant differences in venous levels of TxB2 between the treatment and control groups at baseline or at 10, 30, or 60 minutes postischemia. Neither were there significant intergroup differences in the venoarterial TxB2 gradient at baseline, and at 10, 30, and 60 minutes. Within the treatment and control groups, the venous TxB2 levels and the venous-arterial differences did not change significantly between 10, 30, and 60 minutes. Cerebrospinal fluid levels of TxB2 were elevated in both groups (mean _+ t Gamma counter, manufactured by Packard Instruments Co., Inc., Downers Grove, Illinois. standard error of the mean for the nimodipine-treated group 1670 _+ 185 pg/ml, and for the control group 1 167 _ 240 pg/ml).
Fourteen dogs survived global cerebral ischemia; seven were randomly assigned to receive nimodipine treatment and seven to the control groups. Table 2 presents the cardiovascular data. At baseline, no differences existed in mean arterial blood pressure, heart rate, cardiac output, or pulmonary artery pressures. Ten minutes after global cerebral ischemia (5 minutes prior to treatment), mean arterial pressure and cardiac output were not significantly different between the two groups. Heart rate was greater in the control group than in the treatment group (p = 0.0264). Following nimodipine or the equivalent volume of saline (given 15 minutes postischemia), mean arterial blood pressure, heart rate, and cardiac output were not significantly different be- tween the nimodipine-treated and the control groups.
The global CBF over time, as determined by the microsphere technique, is presented for both groups in Table 3 . There were no group differences at any interval. The CBF data from two dogs in the nimodipine treatment group and one in the control group could not be analyzed due to inadequate reference sampling.
Discussion
During and following global cerebral ischemia, cerebral physiology and metabolism are severely deranged. 6"~4-~6 A delayed postischemic cerebral hypoperfusion state develops at an interval when the cerebral metabolic rate is higher than normal, ~5 and is considerably greater than would be appropriate for the CBF level. Hypoperfusion, occurring at a time when cell integrity must be restored, may potentiate neurological injury. Because hypoperfusion develops following an interval of increased flow, it may be precipitated by the release of a vasoconstrictor metabolite during reperfusion.
Tissue adenosine triphosphate (ATP) depletion occurs 5 to 7 minutes after the onset of ischemia. 15 Without ATP, the sodium-potassium adenosine triphosphate pump fails to maintain transmembrane ionic gradients, causing potassium to leak out of the cell. When extracellular potassium levels approach 15 mM, voltage-dependent calcium gates open, 14 allowing a massive influx of calcium. Increased intracellular calcium levels stimulate phospholipase A2, which converts cell membrane phospholipids to free fatty acids, including arachidonic acid. 5 While the production of many ischemic metabolites, such as lactic acid, reaches a plateau during ischemia, arachidonic acid levels continue to rise. ~5
Following reperfusion, at least 30 minutes elapse * All values are means +_ standard error of the means. BP = blood pressure; MABP = mean arterial blood pressure; CO = cardiac output; PAP = pulmonary arterial pressure; PAWP = pulmonary artery wedge pressure; CVP = central venous pressure; HR = heart rate. before the restoration of normal levels of arachidonic acid. a3 As the abnormally high levels of arachidonic acid axe being metabolized, further cell damage may result from the formation of free radicals, leukotrienes, and vasoconstrictor prostaglandins. '4 There are two major routes of arachidonic acid metabolism (Fig. 2) . The 5-1ipoxygenase enzyme, responsible for the formation of the leukotrienes, has not been documented in the brain, a2 Dempsey, et aL, 4 reported a minimal rise in leukotriene B4 during forebrain isehemia in gerbils. Arachidonic acid is also metabolized by cyclo-oxygenase to the cyclic endoperoxides prostaglandin (PG) G2 and PGH2. Prostaglandin Ha is further metabolized by thromboxane synthetase to TxA2 or by prostacyclin synthetase to PGIa. Dempsey, et aL, reported a prominent increase during isehemia in the metabolic endproducts of TxA2 and PGI2, TxB2, and 6-keto PGF,,. Thromboxane A2 is the most powerful vasoconstrictor among the prostaglandins and, additionally, it activates platelet aggregation. 3 It has a half-life of 30 seconds in vitro. Thromboxane B2 is 1000 times less potent. Prostaglandin I2, a vasodilator and inhibitor of platelet aggregation, is metabolized to PGFI,, a weak vasoconstrictor. Metabolism of the arachidonic acid accumulated during ischemia to TxA2 could explain the hypoperfusion occurring minutes after the cessation of transient global cerebral ischemia.
In a model similar to that used in the present study, intravenously administered ibuprofen, a cyclo-oxygenase inhibitor, improved postischemic CBF while decreasing cerebral venous release of TxBa. 7 In contrast, treatment with a specific thromboxane synthetase inhibitor produced no improvement in CBF. 13 These superficially contradictory results are probably caused by differences in the production of cyclic endoperoxides following inhibition of thromboxane synthetase or cyclo-oxygenase. When thromboxane synthetase is inhibited, cyclic endoperoxides accumulate proximal to the blocked enzymatic step. These compounds, although less potent than TxA2, stimulate thromboxane receptors a (Fig. 2, dashed arrow) . When cyclo-oxygenase is inhibited, the levels of both cyclic endoperoxides and TxA2 decrease.
In this context, one of the theoretically adverse effects of increased intracellular calcium following global cerebral ischemia is the activation of phospholipase A2, with the subsequent accelerated production of toxic arachidonate metabolites. Therefore, the therapeutic effect of nimodipine could be explained in part by antagonism of phospholipase activation. If so, nimodipine should reduce the release within the cerebrovascular system of TxB2. The present study, which conclusively demonstrates that intravascular accumulation of TxB2 is not affected by nimodipine administration, strongly suggests that the therapeutic effect of nimodipine, clearly established in other studies, '~176 does not relate to any interference with phospholipase activation.
These data do not establish the origin of the TxB2 found in jugular venous blood. It could have been released from intravascular platelets or white blood cells, from cerebrovascular endothelial cells, or from brain parenchyma. However, regardless of the site or sites at which TxA2 is produced, the failure of nimodipine to alter arachidonate metabolite release demonstrates that the therapeutic effect of the calcium entry blocker is independent of eicosanoid synthesis. This conclusion is strengthened by the demonstration of similar levels of TxB2 in cerebrospinal fluid, on the opposite side of the blood-brain barrier from the intravascular compartment, at the conclusion of the study.
Previous data have demonstrated that levels of TxB2 measured with a retrograde jugular catheter are comparable to those measured in the sagittal sinus. 7''3 The majority of canine cerebral venous drainage exits through the external jugular vein. Postmortem dissections on several dogs confirmed placement of the tip of the catheter just below the jugular foramen.
In the present study, nimodipine failed to significantly increase postischemic CBF; however, there was FIG. 2. An abbreviated prostaglandin (PG) enzymatic pathway. (1) Phospholipase A2 is an endoenzyme that is stimulated by increased intracellular calcium levels. Phospholipase A2 catalyzes the release of arachidonic acid from membrane lipids. During isehemia, arachidonic acid accumulates because of the oxygen requirement of the lipoxygenases and (2) cyclo-oxygenases. During reperfusion, a sudden increase of cyclic endoperoxides occurs; these could be metabolized (3) to thromboxane (TX) A2, a cerebral vasoconstrictor, or to prostacyclin, a cerebral vasodilator. 5H PETE = 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid; LTB4 = leukotriene B4. In the present study, global cerebral ischemia lasted for 11 minutes in comparison to the 10-minute intervals employed by the other authors, and, unlike studies by Steen and Milde and their colleagues, our investigation used fentanyl to supplement nitrous oxide and intercostal nerve blocks. In addition, we measured CBF using the radiolabeled microsphere method while the other studies employed the sagittal sinus outflow technique. These technical differences take on added significance in light of evidence regarding the heterogeneity of the CBF response following ischemia in nimodipinepretreated rats. Smith, et aL,~7 reported marked interand intra-animal differences in rats pretreated with nimodipine. Using the carbon-14-iodoantipyrine radiographic technique, they discovered 10-fold variations in reflow at 60 minutes in the rat sensorimotor cortex.
It is possible that our CBF data would have agreed with CBF data from previous studies had more animals been entered. However, because the cerebral vasodilatory effect of nimodipine is already well established, the expenditure of additional animals was not justified in light of the conclusive demonstration that postischemic release of TxB2 was unaffected by nimodipine.
This demonstration that nimodipine does not reduce the postischemic production of TxB2 suggests that the mechanism by which nimodipine improves postischemic hypoperfusion does not involve inhibition of TxA2 production. In turn, this raises the possibility that nimodipine, in combination with a cyclo-oxygenase inhibitor, could act synergistically so as to more effectively manage postischemic cerebral hypoperfusion, since each agent operates through a different mechanism. Further studies should determine the efficacy of this therapeutic strategy.
